GlaxoSmithKline: Lung Neoplasms trials
The registry lists 11 Lung Neoplasms studies with GlaxoSmithKline as lead sponsor. 3 are open to participants now and 3 have results posted.
Phase 1 3Phase 2 4Phase 3 4No phase 1(a study in two phases counts in both)
Studies
Open to participants first, then studies with results posted, then the rest; newest registration first within each.
- A Study of Risvutatug Rezetecan in Combination With Ivonescimab in Participants With Advanced Solid Tumors (EMBOLD PanTumour-103)RecruitingNCT07602855Phase 1/2
- A Study of GSK5764227 in Participants With Relapsed Small Cell Lung Cancer (SCLC) [EMBOLD SCLC-301]RecruitingNCT07099898Phase 3
- Neladalkib (NVL-655) for TKI-naive Patients With Advanced ALK-Positive NSCLCRecruitingNCT06765109Phase 3
- Study of TSR-033 With an Anti-programmed Cell Death-1 Receptor (PD-1) in Participants With Advanced Solid TumorsCompletedNCT03250832Phase 1Results posted
- Cancer in Patients With Gabapentin (GPRD)CompletedNCT01236053Results posted
- First-line Treatment Of Subjects With Extensive Disease Small Cell Lung Cancer With Weekly Hycamtin And ParaplatinCompletedNCT00316186Phase 2Results posted
- A Study of HGS1036 in Combination With Chemotherapy in Subjects With Advanced Solid MalignanciesSuspendedNCT01604863Phase 1
- A Study of IV Casopitant for the Prevention of Nausea and Vomiting Caused By Cisplatin-Based Highly Emetogenic ChemotherapyWithdrawnNCT00891761Phase 3
- A Study of Mapatumumab in Combination With Paclitaxel and Carboplatin in Subjects With Non-small Cell Lung CancerCompletedNCT00583830Phase 2
- Active Symptom Control Alone Or In Combination With Oral Topotecan In Patients With Relapsed Resistant Small Cell Lung CancerCompletedNCT00276276Phase 3
- Vinorelbine in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung CancerCompletedNCT00005865Phase 2